Fig. 5: DDX5 regulates IL36R pre-mRNA splicing for sIL-36R production.
a, DNA–PAGE of IL36R and sIL36R transcripts in wild-type and DDX5–/– HeLa cells transfected with 0–3 μg of human IL36R-reporter minigene. b, DNA–PAGE of IL36R and sIL36R transcripts in NHEKs after transduction with siRNA targeting DDX1, DDX3, DDX5, DDX17, DDX23, DDX39, DDX41, DDX42, DDX46 and DDX48. c,d, Immunoblot of sIL-36R in NHEKs transduced with DDX5-targeted siRNA (c) or murine keratinocytes isolated from Ddx5fl/fl and Ddx5∆KC mice (d). e,f, Immunoblot of sIL-36R, IL-36R and IL-36γ in lesional skin from MC903-treated wild-type mice (e) or IMQ-treated wild-type mice (f) at the indicated timepoints. g,h, Immunoblot of sIL-36R in lesional skin from MC903-treated Ddx5fl/fl and Ddx5∆KC mice (g) or IMQ-treated Ddx5fl/fl and Ddx5∆KC mice (h). i,j, Immunoblot of sIL-36R in healthy skin and lesional skin from patients with AD (i) or psoriasis (j). k,l, Immunoblot of sIL-36R in lesional skin from MC903-treated wild-type and Il17d–/–mice (k) or IMQ-treated wild-type and Il17d–/– mice (l). m,n, Immunoblot of sIL-36R in lesional skin from IMQ-treated wild-type and Cd93–/–mice (m) or MC903-treated wild-type and Cd93–/–mice (n).
